March 18, 2022
Life Sciences
  • The Medicines Patent Pool (MPP), a U.N.-backed organization, announced that 35 manufacturers agreed to produce generic forms of Paxlovid – Pfizer’s oral antiviral treatment for COVID-19. Six companies will focus on producing the substance of the drug, nine companies will produce the product, and 20 will do both. According to the MPP, the agreement will enable about 53 percent of the world population to have access to the treatment. (Articles here, here, here, here, and here)